Everolimus

Everolimus is a prescription medicine used in the management of certain cancers and other specific medical conditions. It belongs to a class of medicines known as mammalian target of rapamycin (mTOR) inhibitors. By blocking mTOR signalling, everolimus affects processes involved in cell growth, division and metabolism. It also suppresses aspects of the immune system.

The appropriate use of everolimus depends on the diagnosis, the specific medicine formulation and the applicable prescribing information. This page provides general educational information and an overview of the everolimus products listed by DrMeds.org.

What Is Everolimus Used For?

Everolimus has several established medical uses, depending on the formulation and the patient’s condition. In oncology, certain everolimus products are approved for use in selected patients with hormone receptor-positive, HER2-negative advanced breast cancer, certain neuroendocrine tumours, advanced renal cell carcinoma, and specific manifestations of tuberous sclerosis complex.

Some formulations are also used for particular conditions associated with tuberous sclerosis. Separately, everolimus is used in specialised transplant-medicine regimens to help prevent rejection of certain transplanted organs.

These indications are not interchangeable. Treatment suitability depends on clinical factors, previous treatments, the product’s approved indication and the treating specialist’s assessment. Everolimus is not appropriate for every patient with cancer or for every condition affecting cell growth.

How Does Everolimus Work?

Everolimus inhibits the mTOR pathway, which helps regulate cell growth, proliferation and other cellular functions. In certain diseases, interfering with this pathway can help control abnormal cell growth. Its effects on immune activity also explain its role in selected transplant regimens.

The medicine’s benefits and risks vary according to the condition being treated. Its use requires an appropriate medical assessment and monitoring by a qualified healthcare professional.

Available Everolimus Products at DrMeds.org

DrMeds.org lists the following everolimus products on this molecule page:

• LUCIEVER Everolimus 5 mg Tablet
• LUCIEVER Everolimus 10 mg Tablet

Please visit the respective product pages for the listed product details, manufacturer information and enquiry options.

The strengths shown above are separate product listings; they should not be considered interchangeable treatment recommendations. The appropriate strength and regimen must be determined by the prescribing specialist. Product listing does not guarantee current stock, supply availability or suitability for a particular patient.

For product enquiries, contact DrMeds.org to request current availability information, relevant product documentation and details of prescription requirements. A valid prescription may be required, subject to the applicable regulations.

Important Safety Information

Everolimus can cause serious adverse effects and requires medical supervision. Depending on the formulation and treatment indication, important risks can include infections, mouth ulcers or inflammation, changes in blood glucose and blood lipids, impaired wound healing, and lung inflammation that is not caused by infection.

Patients should tell their healthcare professional about all medicines and supplements they use, existing medical conditions, planned surgery, infections, and pregnancy or breastfeeding considerations. Everolimus can interact with other medicines, so a prescriber or pharmacist should check for clinically important interactions.

Monitoring may include blood tests and assessments of kidney function, blood glucose, blood lipids and other parameters according to the treatment regimen. Patients should not start, stop or change the dose without instructions from their treating healthcare professional.

Seek prompt medical advice if concerning symptoms develop. Severe breathing difficulty, a serious allergic reaction or other potentially life-threatening symptoms require emergency medical attention.

Frequently Asked Questions

Is everolimus a chemotherapy medicine?

Everolimus is generally classified as a targeted therapy and an mTOR inhibitor, rather than a conventional cytotoxic chemotherapy medicine. Its precise role depends on the diagnosis and treatment regimen.

What strengths of everolimus are listed on DrMeds.org?

This page lists LUCIEVER Everolimus 5 mg and LUCIEVER Everolimus 10 mg tablets. Refer to each individual product page for product-specific details and contact DrMeds.org to enquire about availability.

Can everolimus be used for every type of cancer?

No. Its approved uses are limited to particular conditions and patient groups. A cancer specialist must determine whether everolimus is appropriate for an individual’s diagnosis and clinical circumstances.

What side effects can everolimus cause?

Possible adverse effects include mouth ulcers, infections, changes in blood glucose or cholesterol, delayed wound healing and lung inflammation. The type and likelihood of side effects depend on the treatment and patient. Consult the product leaflet and prescribing specialist for complete safety information.

Does everolimus require a prescription?

Everolimus is a prescription medicine in many jurisdictions. Patients should follow the prescribing and dispensing requirements that apply in their country and obtain it through an authorised supply channel.

How can I enquire about everolimus products?

Review the individual LUCIEVER product listings on DrMeds.org and use the site’s contact or enquiry options to request current product information. Availability should be confirmed before any purchase or treatment decision.

Medical Disclaimer

This page is for general educational purposes only and does not replace professional medical advice, diagnosis or treatment. Everolimus should be used only under the supervision of an appropriately qualified healthcare professional. Always consult the current prescribing information for the specific product.

Medical References

1. National Cancer Institute (NCI). Everolimus — Drug Information. https://www.cancer.gov/about-cancer/treatment/drugs/everolimus
2. U.S. National Library of Medicine, DailyMed. Afinitor / Afinitor Disperz — Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2150f73a-179b-4afc-b8ce-67c85cc72f04
3. U.S. National Library of Medicine, DailyMed. Zortress — Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e082a024-7850-400b-a5c2-2a140612562a

Content review date: 18 October 2026
Medical review status: Pending review by a qualified medical professional before publication.